In late 2022, the Korean Pharma Association did an evaluation of over 200 drugs that were approved in Korea between 2011 – 2022. Western countries and Japan have been able to reduce the review times for new drug approvals, but during this... Read More
Decentralized clinical trials in China are growing due to a variety of reasons. First, China is a large geographic area (the same geographic size as the US) where most advanced medical research is concentrated in its big cities. However, many patients find... Read More
Due to the relaxation of China’s zero COVID policy and government investment in Chinese hospitals, the demand for medical devices in China should grow in 2023. With more Chinese getting COVID now, Chinese hospitals are seeing a dramatic rise in equipment needs.... Read More
A recent study by a research department at the Japan Pharmaceutical Manufacturer Association (JPMA) outlines how many Japanese and foreign drug companies are not increasing (and in some cases decreasing) their investment and focus in Japan’s drug market. One of the many... Read More
In 2020, the Chinese NMPA established the Rare Diseases Registry. Since then, more foreign and local drug companies have been interested in getting their rare disease drugs into China. According to GlobalData’s Drugs Intelligence Database, there are now 378 drugs for rare... Read More
Japan’s MHLW is hoping to increase its fiscal year 2023 budget in a number of healthcare areas to promote better healthcare. An additional $3 million dollars is proposed to help cancer drug research via AI data analysis. This research is being done... Read More
The Korean government plans to increase Korea’s drug and biotechnology markets by adopting more global standards, implementing positive regulatory policies, and increasing investment. The Korean government hopes to develop a super fund to support its vaccine and new drug development. First, Korea... Read More
On June 28, the NMPA said it plans to improve services to foreign medical companies. Primarily, this message is to further help foreign drug and medical device companies with more efficient product registration. Their focus will be primarily on the pediatric and rare disease... Read More
Opportunities in China for novel drugs will continue to grow despite recent NRDL price cuts. For example, Novartis sales in China are close to $3.1 billion a year, and last year sales grew by double digits. 2025 sales are expected to top $4.2 billion... Read More
Digital healthcare trends are flourishing in Asia due to its aging population, shortage of healthcare personnel, increasing consumer demand, and technological innovation. According to statistics from Graphical Research, the digital health market in Asia Pacific is expected to grow by 33% from 2020... Read More